  |
 | Up a level |
Wiviott, S.D. and Raz, I. and Bonaca, M.P. and Mosenzon, O. and Kato, E.T. and Cahn, A. and Silverman, M.G. and Zelniker, T.A. and Kuder, J.F. and Murphy, S.A. and Bhatt, D.L. and Leiter, L.A. and McGuire, D.K. and Wilding, J.P.H. and Ruff, C.T. and Gause‑Nilsson, I.A.M. and Fredriksson, M. and Johansson, P.A. and Langkilde, A.-M. and Sabatine, M.S. and for the DECLARE–TIMI 58 Investigators* and Ukraine: and Karpenko, O. and Tkach, S. and Vlasenko, M. and Fushtey, I. and Pertseva, T. and Reshotko, D. and Mostovoy, Y. and Vizir, V. and Kraiz, I. and Amosova, K. and Batushkin, V. and Tseluyko, V. and Koval, O. (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine = N Engl J Med, 380 (4). pp. 347-357. ISSN 0028-4793 (print); 1533-4406 (online)
Eikelboom, J.W. and Connolly, S.J. and Bosch, J. and Dagenais, G.R. and Hart, R.G. and Shestakovska, O. and Diaz, R. and Alings, M. and Lonn, E.M. and Anand, S.S. and Widimsky, P. and Hori, M. and Avezum, A. and Piegas, L.S. and Branch, K.R.H. and Probstfield, J. and Bhatt, D.L. and Zhu, J. and Liang, Y. and Maggioni, A.P. and Lopez‑Jaramillo, P. and O’Donnell, M. and Kakkar, A.K. and Fox, K.A.A. and Parkhomenko, A.N. and Ertl, G. and Störk, S. and Keltai, M. and Ryden, L. and Pogosova, N. and Dans, A.L. and Lanas, F. and Commerford, P.J. and Torp‑Pedersen, C. and Guzik, T.J. and Verhamme, P.B. and Vinereanu, D. and Kim, J.-H. and Tonkin, A.M. and Lewis, B.S. and Felix, C. and Yusoff, K. and Steg, P.G. and Metsarinne, K.P. and Cook Bruns, N. and Misselwitz, F. and Chen, E. and Leong, D. and Yusuf, S. and Koval, O. and Kaplan, P. and Ivanov, A. and Romanenko, S. and Skoromna, A. (2017) Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. The New England Journal of Medicine, 377 (14). pp. 1319-1330. ISSN 0028-4793
